Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275923 | 0.83 | ALDH1A1 (0.46) | ALDH1A1NPC1POLBRAB9ACYP3A4 | |
| SCHEMBL25164 | 0.76 | MAPT (0.55) | ALDH1A1NPC1POLBRAB9ACYP3A4 | |
| SCHEMBL24520 | 0.73 | CCR1 (0.52) | ALDH1A1NPC1CYP3A4KDM4EHTT | |
| SCHEMBL17511860 | 0.72 | MAPT (0.55) | ALDH1A1NPC1POLBRAB9ACYP3A4 | |
| SCHEMBL131542 | 0.71 | ALDH1A1 (0.52) | ALDH1A1NPC1POLBRAB9ACYP3A4 | |
| SCHEMBL3936146 | 0.71 | — | — | |
| SCHEMBL9196 | 0.70 | MAPT (0.36) | ALDH1A1KDM4EMAPTHSP90AA1CYP1A2 | |
| SCHEMBL3941104 | 0.70 | — | — | |
| SCHEMBL24690 | 0.69 | CCR1 (0.52) | ALDH1A1CYP3A4KDM4EHTTMAPT | |
| SCHEMBL29683629 | 0.69 | ALDH1A1 (0.54) | ALDH1A1NPC1POLBRAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-2897618-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2021-11-17 | — | — | EP | claimed |
| US-10457641-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20170334859-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-11-23 | — | — | US | claimed |
| US-9688635-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2017-06-27 | — | — | US | claimed |
| US-20150246885-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-09-03 | — | — | US | claimed |
| EP-2897618-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2015-07-29 | — | — | EP | claimed |
| EP-0728130-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0385662-B1 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LTD (GB) | 1995-12-13 | — | — | EP | claimed |
| EP-0385663-B1 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-12-06 | — | — | EP | claimed |
| WO-1995013267-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | THE UPJOHN COMPANY (US) | 1995-05-18 | — | — | WO | claimed |
| EP-0420511-B1 | Heterocyclic derivatives | ICI PLC (GB) | 1994-08-17 | — | — | EP | claimed |
| EP-0381375-B1 | HETEROCYCLIC DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-11 | — | — | EP | claimed |
| EP-0420511-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-03 | — | — | EP | claimed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | claimed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | claimed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | ALDH1A1 4711/4885NPC1 545/4885POLB 3627/4885 |
| US-10457641-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | ALDH1A1 1767/4885NPC1 1884/4885POLB 1809/4885 |
| US-20150246885-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | BRAF, AURKC, PLK1 | ALDH1A1 1698/4885NPC1 1984/4885POLB 2484/4885 |
| US-20170334859-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | ALDH1A1 1767/4885NPC1 1884/4885POLB 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.